WHX 2026｜Shanghai Sun Biotech’s Comprehensive Coagulation Solution Highly Recognized by International Clients

From February 10 to 13, 2026, the World Health Expo (WHX) was held at the Dubai World Trade Centre. As one of the most influential professional exhibitions in the global medical device industry, this year’s event attracted more than 4,300 exhibitors from over 180 countries and regions. Shanghai Sun Biotech presented its complete coagulation testing portfolio, showcasing to the global market the company’s technological depth and innovation capabilities in the field of thrombosis and hemostasis.

Comprehensive Test Coverage to Elevate Clinical Diagnostics

During the exhibition, under the theme of a “Comprehensive Coagulation Testing Solution,” Shanghai Sun Biotech highlighted its full reagent portfolio covering routine coagulation screening, coagulation factor assays, thrombophilia diagnostics, and anticoagulation therapy monitoring. Numerous laboratory professionals engaged in in-depth discussions regarding product performance, clinical applications, and laboratory implementation, creating a dynamic and highly interactive atmosphere on site. Although the clinical value of specialized coagulation assays is well recognized, their broader adoption in many regions has long been constrained by reagent costs. Shanghai Sun Biotech continues to optimize testing costs through sustained innovation in R&D, supply chain coordination, and large-scale manufacturing, enabling advanced coagulation technologies to benefit more countries and healthcare systems worldwide.

Multi-Level Instrument Portfolio Responding to Diverse Global Needs

Global healthcare markets vary significantly. Large central laboratories prioritize efficiency and automation, while regional healthcare institutions place greater emphasis on cost-effectiveness and practical usability. In response, Shanghai Sun Biotech showcased a multi-tier coagulation instrument portfolio at this exhibition: the UR Series constant-speed fully automated coagulation analyzers and the UL-2000LAS intelligent laboratory automation system are designed for high-throughput testing in large laboratories; the UG Series, featuring photo-magnetic aggregation technology, effectively addresses interference from lipemia, icterus, and hemolysis, meeting the needs of mid-sized laboratories handling complex sample types and diverse testing requirements; and the UP Series focuses on balancing performance and cost, supporting routine testing demands in small and medium-sized laboratories. Through this systematic instrument deployment, the company has established scalable solutions tailored to laboratories of different sizes, enhancing the flexibility and adaptability of coagulation testing across varied clinical settings.

Dubai, strategically located at the crossroads of Asia, Europe, and Africa, serves as a key hub for advancing the “Health Silk Road” initiative. At this year’s WHX, Shanghai Sun Biotech’s comprehensive coagulation testing solution—built upon 25 years of dedicated R&D—garnered widespread attention from professionals across numerous countries and regions. Taking this exhibition as a new starting point, Shanghai Sun Biotech will continue to deepen its global strategic expansion, driving Chinese coagulation diagnostics onto the world stage through technological innovation and open collaboration.